[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Ribociclib",
            "Result": [
                "Score: -2  \nReasoning:  \nThe hypothesis states that treatment with ribociclib will worsen outcomes for patients with breast cancer. However, across all five reported trials (PMIDs: 305223, 100775, 973683, 772719, 417353), ribociclib did not lead to significantly worse survival outcomes compared to control. In each study, the hazard ratios for progression-free survival (PFS) and overall survival (OS) hovered around 1 (e.g., HR \u2248 0.95\u20131.03), indicating no statistically significant difference compared to placebo plus letrozole. Although the ribociclib arms showed higher rates of adverse events (notably neutropenia and fatigue), none of these trials demonstrated worsened clinical outcomes (i.e., shorter PFS or OS) attributable to ribociclib. Thus, the consistent lack of evidence for harm refutes the hypothesis."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 305223. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Ribociclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Negative Outcome Study  \n\n**Abstract**  \n\n**Objective:** To assess the efficacy and clinical outcomes of ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by menopausal status, prior endocrine therapy, and visceral metastasis.  \n\n**Participants:** A total of 624 postmenopausal women with HR+/HER2- advanced breast cancer were enrolled across 78 sites. Eligible participants had measurable disease per RECIST v1.1 and no prior CDK4/6 inhibitor exposure.  \n\n**Interventions:** Patients were randomized 1:1 to receive ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) or placebo plus letrozole. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** After a median follow-up of 24.5 months, no significant difference in PFS was observed between the ribociclib and placebo arms (median PFS: 18.2 vs. 17.8 months; hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.79\u20131.14; p = 0.58). Similarly, OS data showed no benefit (median OS: 42.1 vs. 41.7 months; HR 0.98, 95% CI 0.82\u20131.18; p = 0.83). ORR was comparable between groups (32.4% vs. 30.1%, p = 0.47). Adverse events were more frequent with ribociclib, including neutropenia (58.3% vs. 4.2%) and fatigue (28.6% vs. 18.9%).  \n\n**Conclusions:** In this randomized phase III trial, ribociclib combined with letrozole did not demonstrate a statistically significant improvement in PFS or OS compared to letrozole alone in HR+/HER2- advanced breast cancer. These findings suggest limited clinical benefit in an unselected patient population, warranting further biomarker-driven studies to identify potential responders.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 100775. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Ribociclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study  \n\n**Objective:** To assess the efficacy of ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, in combination with endocrine therapy versus endocrine therapy alone in patients with advanced hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer, focusing on progression-free survival (PFS) and overall survival (OS).  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by metastatic site, prior endocrine therapy, and menopausal status.  \n\n**Participants:** A total of 624 postmenopausal women with HR+/HER2- advanced breast cancer were enrolled across 78 institutions. Eligible participants had measurable disease per RECIST v1.1 and no prior CDK4/6 inhibitor exposure.  \n\n**Interventions:** Patients were randomized 1:1 to receive ribociclib (600 mg/day, 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint: PFS. Secondary endpoints: OS, objective response rate (ORR), clinical benefit rate (CBR), and safety.  \n\n**Results:** Median follow-up was 24.5 months. Median PFS was 14.2 months (95% CI, 12.8\u201316.1) in the ribociclib arm versus 13.8 months (95% CI, 11.9\u201315.4) in the placebo arm (HR 0.97; 95% CI, 0.82\u20131.15; p=0.72). No significant difference in OS was observed (HR 1.03; 95% CI, 0.86\u20131.24; p=0.75). ORR was 32.5% vs. 30.1% (p=0.51), and CBR was 65.2% vs. 63.8% (p=0.69). Grade 3/4 adverse events were more frequent with ribociclib (neutropenia: 45.3% vs. 2.1%; fatigue: 12.7% vs. 8.4%).  \n\n**Conclusions:** In this randomized phase III trial, ribociclib combined with letrozole did not demonstrate a statistically significant improvement in PFS or OS compared to letrozole alone in HR+/HER2- advanced breast cancer. The lack of clinical benefit, coupled with increased toxicity, suggests limited utility in this patient population. Further biomarker-driven studies may identify subsets that could derive benefit.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 973683. **Title:** A Phase III Randomized Controlled Trial Evaluating the Efficacy of Ribociclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Negative Outcome Study  \n\n**Abstract**  \n\n**Objective:** To assess the efficacy and safety of ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by menopausal status and prior endocrine therapy.  \n\n**Participants:** A total of 648 postmenopausal women with HR+, HER2- advanced breast cancer were enrolled between January 2018 and December 2020. Eligible participants had measurable disease per RECIST v1.1 and no prior CDK4/6 inhibitor exposure.  \n\n**Interventions:** Patients were randomized 1:1 to receive ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) or placebo plus letrozole. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median follow-up was 24.5 months. No significant difference in PFS was observed between the ribociclib and placebo arms (median PFS: 18.2 vs. 17.8 months; hazard ratio [HR] 0.97, 95% CI 0.79\u20131.19; *p* = 0.78). Similarly, OS did not differ significantly (median OS: 42.1 vs. 41.3 months; HR 1.02, 95% CI 0.84\u20131.24; *p* = 0.85). ORR was comparable between groups (32.4% vs. 30.1%; *p* = 0.54). Grade 3/4 adverse events were more frequent with ribociclib (neutropenia: 45.2% vs. 3.1%; fatigue: 12.4% vs. 8.7%).  \n\n**Conclusions:** In this randomized phase III trial, the addition of ribociclib to letrozole did not significantly improve PFS or OS in patients with HR+, HER2- advanced breast cancer. The lack of clinical benefit, coupled with increased toxicity, suggests limited utility of ribociclib in this setting. Further biomarker-driven studies may identify subsets of patients who could derive benefit.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 772719. **Abstract**  \nRibociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been widely investigated in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer as part of combination therapy with endocrine agents. This multicenter, randomized, double-blind, placebo-controlled phase III trial evaluated the efficacy and safety of ribociclib plus letrozole versus letrozole alone in postmenopausal women with HR+/HER2- metastatic breast cancer (MBC). A total of 672 patients were enrolled and stratified by visceral metastasis and prior endocrine therapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. After a median follow-up of 42.3 months, the median PFS was 18.7 months (95% CI, 16.5\u201321.0) in the ribociclib arm versus 16.4 months (95% CI, 14.2\u201318.1) in the placebo arm (hazard ratio [HR], 0.91; 95% CI, 0.77\u20131.08; p=0.28). No statistically significant difference in OS was observed, with median OS of 48.2 months (95% CI, 43.1\u201352.9) for ribociclib versus 46.8 months (95% CI, 41.5\u201350.7) for placebo (HR, 0.95; 95% CI, 0.82\u20131.10; p=0.47). The ORR was comparable between groups (42.5% vs. 39.8%; p=0.41). Adverse events were consistent with prior reports, with neutropenia (63.2%) and fatigue (32.1%) being most frequent in the ribociclib arm. These findings suggest that the addition of ribociclib to letrozole does not confer a statistically significant improvement in PFS or OS in this patient population, challenging the presumed clinical benefit of CDK4/6 inhibition in unselected HR+/HER2- MBC. Further biomarker-driven studies are warranted to identify subsets that may derive meaningful benefit from ribociclib therapy.\n\n---\n\nPMID: 417353. **Title:** *A Phase III Randomized Controlled Trial Evaluating the Efficacy of Ribociclib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Negative Outcome Study*  \n\n**Background:** Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been widely investigated in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. While preclinical data suggest potent antitumor activity, clinical outcomes in real-world settings remain uncertain. This study aimed to assess the efficacy of ribociclib in combination with endocrine therapy versus endocrine therapy alone.  \n\n**Methods:** In this multicenter, randomized, double-blind, placebo-controlled trial, 450 postmenopausal women with HR+/HER2- advanced breast cancer were enrolled (*Population*). Patients were randomized 1:1 to receive either ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) (*Intervention*) or placebo plus letrozole (*Comparison*). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety (*Outcomes*).  \n\n**Results:** After a median follow-up of 24 months, no significant difference in PFS was observed between the ribociclib and control arms (median PFS: 18.2 vs. 17.8 months; hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.78\u20131.16; *p* = 0.62). Similarly, OS did not differ significantly (median OS: 42.1 vs. 41.3 months; HR 0.98, 95% CI 0.82\u20131.18; *p* = 0.84). ORR was comparable between groups (32.5% vs. 30.1%; *p* = 0.54). Adverse events were more frequent with ribociclib, including neutropenia (45% vs. 12%) and fatigue (28% vs. 15%).  \n\n**Conclusion:** In this large randomized trial, the addition of ribociclib to letrozole did not significantly improve PFS or OS in patients with HR+/HER2- advanced breast cancer. These findings suggest limited clinical benefit in this population, warranting further investigation into predictive biomarkers for CDK4/6 inhibitor response.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Keywords:** Ribociclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, progression-free survival, negative trial\n\nAvailable PMIDs for Citation: 305223, 100775, 973683, 772719, 417353\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Ribociclib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Ribociclib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Ribociclib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Ribociclib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Ribociclib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Ribociclib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Ribociclib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Ribociclib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Ribociclib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Ribociclib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Ribociclib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/305223/",
                    "https://pubmed.ncbi.nlm.nih.gov/100775/",
                    "https://pubmed.ncbi.nlm.nih.gov/973683/",
                    "https://pubmed.ncbi.nlm.nih.gov/772719/",
                    "https://pubmed.ncbi.nlm.nih.gov/417353/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]